Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA2 | P00918 | 8/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19591348 | 0.92 | MALT1 (0.49) | CA1CA2BRD4CA12CA9 | |
| SCHEMBL16024065 | 0.86 | MAPT (0.51) | CA1CA2BRD4STK17BSTK17A | |
| SCHEMBL10126690 | 0.85 | MTNR1A (0.60) | CA1CA2BRD4STK17BSTK17A | |
| SCHEMBL16024081 | 0.85 | CA1 (0.49) | CA1CA2BRD4STK17BSTK17A | |
| SCHEMBL2991645 | 0.85 | MAPK1 (0.53) | CA1CA2BRD4STK17BSTK17A | |
| SCHEMBL17471214 | 0.85 | CA1 (0.49) | CA1CA2BRD4STK17BSTK17A | |
| SCHEMBL10126784 | 0.84 | MEN1 (0.53) | CA1CA2BRD4STK17BSTK17A | |
| SCHEMBL24670062 | 0.83 | CA2 (0.74) | CA1CA2CA12CA9 | |
| SCHEMBL15584781 | 0.81 | CA1 (0.62) | CA1CA2TDP1GAAALDH1A1 | |
| SCHEMBL31654213 | 0.81 | MAPT (0.52) | CA1CA2BRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596535-A1 | DRUG FOR TREATING HUMAN TUMOR BY ERF3A TARGETED PROTEIN DEGRADATION MECHANISM | Suzhou Degen Bio-Medical Co, Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | SUZHOU DEGEN BIO-MEDICAL CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| CN-118119598-A | Medicine for treating human tumor by eRF3a targeting protein degradation mechanism | 苏州德亘生物医药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117801051-A | Medicine for treating human tumor by eRF3a targeting protein degradation mechanism | 苏州德亘生物医药有限公司 | 2024-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | XIAP, TP53, UBE3A | CA1 2323/4885CA2 3381/4885BRD4 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.